The potential for the development of renewable energy generation in Russian territories where the power supply system is decentralized

The problem of conservation of energy sources is actual in many countries. The energy strategies of developed countries are aimed at renewable energy sources. For instance, European Union has already developed a long-term strategy ENERGYSTRATEGY 2050 aimed to reduce greenhouse gas emission by more than 80-95% from 1990 levels. Russian Federation has also developed the national program "Energy saving and improvement of energy efficiency for the period until 2030". The distinctive feature of Russian energy system development is decentralized energy supply on large territories. Therefore, the renewable energy development is urgent. This article describes prospective directions of development of renewable energy generation systems in underpopulated and isolated territories of the Russian Federation where energy supply is decentralized. © Published under licence by IOP Publishing Ltd

Способ получения рекомбинантных антител, продуцируемых клеточной линией, трансдуцированной рекомбинантными аденовирусами

Objectives. To develop a technology for obtaining recombinant antibodies in a suspension culture of human HEK293 cells using transduction with recombinant adenovirus serotype 5 (rAd5) carrying genes expressing heavy and light chains of antibodies on the example of two broadspectrum anti-influenza antibodies 27F3 and CR9114.Methods. Ad5-27F3-H, Ad5-CR9114-H, and Ad5-27F3-L recombinant adenoviruses carrying the 27F3 antibody heavy chain gene, CR9114 antibody heavy chain gene, and 27F3 light chain gene, respectively, were generated using the AdEasy™ Adenoviral vector system. To accumulate preparative amounts of recombinant r27F3 and rCR9114 antibodies, the HEK293 suspension cell line was transduced with recombinant adenoviruses carrying genes for heavy and light chains of antibodies. The cells were cultured in a wave-type bioreactor. Chromatography was used to purify recombinant antibodies from the culture medium. After analyzing the molecular weights of purified antibodies using protein electrophoresis, their ability to interact with influenza A and B viruses was analyzed using the Western blot technique, while their ability to neutralize influenza A and B viruses was evaluated using the virus neutralization assay.Results. A method for the accumulation and purification of recombinant r27F3 and CR9114 antibodies from the culture medium of a suspension culture of human cells following transduction with its recombinant adenoviruses carrying the genes for heavy and light chains of these antibodies was developed. The ability of the r27F3 antibody to interact with and neutralize influenza A viruses of group 1 (except influenza A virus subtype H2) and group 2 was shown. The ability of the rCR9114 antibody to interact with influenza A viruses of group 1 and influenza B viruses, as well as to neutralize influenza A viruses of group 1, was demonstrated.Conclusions. A technology for obtaining recombinant antibodies in a suspension culture of HEK293 cells using transduction with recombinant adenoviruses carrying genes expressing heavy and light chains of antibodies was developed along with a confirmation of their specificity.Цели. Разработать технологию получения рекомбинантных антител в суспензионной культуре клеток человека HEK293 с помощью трансдукции рекомбинантными аденовирусами человека пятого серотипа, несущими гены, экспрессирующие тяжелые и легкие цепи антител, на примере двух противогриппозных антител широкого спектра действия 27F3 и CR9114.Методы. Рекомбинантные аденовирусы Ad5-27F3-H, Ad5-CR9114-H и Ad5-27F3-L, несущие ген тяжелой цепи антитела 27F3, ген тяжелой цепи антитела CR9114 и ген легкой цепи 27F3, были получены с помощью набора AdEasy™ Adenoviral vector system. Для накопления препаративных количеств рекомбинантных антител r27F3 и rCR9114 суспензионную клеточную линию HEK293 трансдуцировали рекомбинантными аденовирусами, несущими гены тяжелых и легких цепей антител, и культивировали клетки в биореакторе волнового типа. Рекомбинантные антитела очищали из культуральной жидкости хроматографическим методом. Молекулярную массу полученных антител анализировали с помощью белкового электрофореза, их способность взаимодействовать с вирусами гриппа А и В методом вестерн-блот анализа, а способность нейтрализовать вирусы гриппа А и В с помощью реакции вирус-нейтрализации.Результаты. Отработана методика накопления и очистки рекомбинантных антител r27F3 и CR9114 из культуральной жидкости суспензионной культуры клеток человека после трансдукции ее рекомбинантными аденовирусами, несущими гены тяжелых и легких цепей этих антител. Показана способность антитела r27F3 взаимодействовать с вирусами гриппа А подгруппы 1 (кроме вируса грипп А субтипа H2) и подгруппы 2 и нейтрализовать их. Показана способность антитела rCR9114 взаимодействовать с вирусами гриппа А подгруппы 1 и вирусами гриппа В, а также нейтрализовать вирусы гриппа А подгруппы 1.Выводы. Отработана технология получения рекомбинантных антител в суспензионной культуре клеток HEK293 с помощью трансдукции рекомбинантными аденовирусами, несущими гены, экспрессирующие тяжелые и легкие цепи антител, и показана их специфичность

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Application of Green Building Technologies in Urals Region

A tendency to build high-rise buildings is common for all developing Russian cities. Sustainability and energy efficiency of such buildings are issues of foremost importance besides the strength and reliability of building structures. Nowadays, both of these terms are united in the concept of "green building". The green building concept includes design, construction, and service of buildings aimed at creating comfortable microclimate, increasing energy efficiency, and reducing the environmental impact. In this work the analysis of distinctive features of designing green buildings in Ural region is given on the example of high-rise buildings constructed in Ekaterinburg. The influence of green building technologies on architectural, planning, and design solutions and selection of construction materials is explored as well as aspects of aerodynamics inside and outside the building. The influence of air flows on air permeability of building structures is assessed. The article also describes innovative solutions for creating required microclimate inside the building. © Published under licence by IOP Publishing Ltd

Computer simulation-based analysis of wind load effect on structural capacity of skywalk between Hyatt Regency hotel and multipurpose building complex Iset Tower in Ekaterinburg

This article contains a computer - aided analysis of bearing capacity under wind load for a standard attachment fixture which one is most frequently used for mounting transparent structures. The analysis results of peak positive and negative wind loads acting on the enveloping structure are presented. The stress-strain state of the skywalk facade fixture unit in the elastic strain stage is analyzed. Maximal values of force influence on the plastic deformation of the fixture unit components arise. They are determined on the basis of a nonlinear analysis. The object of the research is a skywalk between the Hyatt Regency hotel building and the Iset Tower high-rise building in Ekaterinburg that is being designed currently. Simulation models and computational experiments were made in ANSYS CFX software complex. © Published under licence by IOP Publishing Ltd.The work was supported by Act 211 Government of the Russian Federation, contract № 02.A03.21.0006

Collective Immunity to Virus Measles of Medical Workers and Students of Medical Colleges in the Republic of Tatarstan

Relevance. Within the framework of the state assignment in the, Kazan Scientific Research Institute of Epidemiology and Microbiology together with the Department of Rospotrebnadzor in the Republic of Tatarstan, the analysis of the tensions of collective immunity to measles in at-risk groups among medical workers, students of medical colleges in Kazan, Naberezhnye Chelny, Buinsk and Muslyumovsky districts for the period 2015‒2017.Materials and methods. Immunoenzyme method of analysis studied the intensity of immunity against measles in 1107 serum samples of medical workers from 19 medical and preventive institutions in cities and some regions of the Republic of Tatarstan, and students of medical schools and colleges.Results. It was established that out of 480 medical personnel, 363 (75,63 ± 2,253%) were seropositive to the measles virus, and 117 (24.38 ± 3.969%) were seronegative. Coverage by vaccination and revaccination against measles among the sample group of medical workers did not reach the level of 93% (84.38 ± 1.657%), which does not prevent the outbreak of measles among this group. According to the results of a sample survey of antibodies to measles virus among students of medical schools and colleges of the Republic of Tatarstan (data for 2016 and 2017), it was found that the proportion of seronegative measles virus among students in large cities of the Republic of Tatarstan in 2016 was 52.35 ± 2,99%, and in 2017, 42.32 ± 2.958% of the people. The proportion of students who were seronegative for measles virus for two years of the study (2016–2017) averaged 45.07 ± 2.979%.Discussion and conclusions. The results indicate the need to continue conducting studies on seromonitoring of collective immunity to measles in medical workers, students in secondary and higher medical schools